Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

NCT07233499 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Nebivolol 5 mg

Sponsor

Ain Shams University

Collaborators

[object Object]